PROGRAF 5 MG
TACROLIMUS : 5 MG · DIN 02176009 · ASTELLAS PHARMA CANADA INC
Health Canada status: MARKETED
What is PROGRAF?
PROGRAF 5 MG contains TACROLIMUS : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02176009, held by ASTELLAS PHARMA CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 15-Sep-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROGRAF used for?
Prograf® (tacrolimus) is indicated for: prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants; treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants. Prograf (tacrolimus immediate - release capsules, USP) is indicated for: treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti - rheumatic drug (DMARD) therapy is ineffective or inappropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is PROGRAF called?
The same molecule, TACROLIMUS, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Tacrolimus Sandoz | Latin | Australia |
| ADVAGRAF XL | Latin | Australia |
| Tacrolimus XR Sandoz | Latin | Australia |
| Tacrograf | Latin | Australia |
| Dailiport | Latin | Czechia, Iceland |
| ADVAGRAF | Latin | Bahrain, Czechia |
| Pacrolim | Latin | Australia |
| PROTOPIC | Latin | Bahrain, Czechia |
| Advagraf (Lyfjaver) | Latin | Iceland |
| Modigraf | Latin | Czechia, Iceland |
| Rolitac XL | Latin | Saudi Arabia |
| TACFORIUS | Latin | Czechia |
| ARNALTEM | Latin | Saudi Arabia |
| ENVARSUS | Latin | Czechia |
| Prograf (Lyfjaver) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02176009 |
|---|---|
| Brand name | PROGRAF |
| Generic / active ingredient | TACROLIMUS : 5 MG |
| Manufacturer | ASTELLAS PHARMA CANADA INC |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L04AD02 TACROLIMUS |
| AHFS class | 90:28.28.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Sep-2005 |
| Original market date | 1996-08-14 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02176009 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2176009 |
| Brand name | PROGRAF |
| Active ingredient / INN | TACROLIMUS : 5 MG |
| ATC code | L04AD02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04 |
| AHFS class | 90:28.28.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ASTELLAS PHARMA CANADA INC |
How is it stored and handled?
The diluted solution for infusion should be stored at 15 - 25°C in glass or polyethylene containers and should be discarded after 24 hours.
How is it supplied?
100-count bottles or in blister packs of 100 capsules (10 capsules per card) for 0.5 mg, 1 mg, and 5 mg capsules; boxes of 10 ampoules for 5 mg/mL injection
Which pack is which?
| Strength on the label | 5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Packaging as described in the monograph | 100-count bottles or in blister packs of 100 capsules (10 capsules per card) for 0.5 mg, 1 mg, and 5 mg capsules; boxes of 10 ampoules for 5 mg/mL injection |
| Storage | The diluted solution for infusion should be stored at 15 - 25°C in glass or polyethylene containers and should be discarded after 24 hours. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code L04AD02 TACROLIMUS. 21 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-TACROLIMUS | 0.5 MG | CAPSULE (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02454068 |
| ACH-TACROLIMUS | 1 MG | CAPSULE (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02456095 |
| ACH-TACROLIMUS | 5 MG | CAPSULE (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02456109 |
| ADVAGRAF | 0.5 MG | CAPSULE (EXTENDED RELEASE) | ASTELLAS PHARMA CANADA INC | MARKETED | DIN 02296462 |
| ADVAGRAF | 1 MG | CAPSULE (EXTENDED RELEASE) | ASTELLAS PHARMA CANADA INC | MARKETED | DIN 02296470 |
| ADVAGRAF | 3 MG | CAPSULE (EXTENDED RELEASE) | ASTELLAS PHARMA CANADA INC | MARKETED | DIN 02331667 |
| ADVAGRAF | 5 MG | CAPSULE (EXTENDED RELEASE) | ASTELLAS PHARMA CANADA INC | MARKETED | DIN 02296489 |
| ENVARSUS PA | 0.75 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02485877 |
| ENVARSUS PA | 1 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02485885 |
| ENVARSUS PA | 4 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02485893 |
Who else supplies TACROLIMUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TACROLIMUS appears in 609 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does TACROLIMUS cost around the world?
TACROLIMUS is listed on 17 national price registers Nexara tracks, across 430 pack listings published on 15 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 9 | 96 | 08 Sep 2026 |
| United States | acquisition | 5 | 72 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 34 | 34 | 02 Sep 2026 |
| Saudi Arabia | public | 23 | 32 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 23 | 26 | 03 Sep 2026 |
| South Africa | single exit price | 20 | 25 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 8 | 24 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 17 | 18 | 03 Sep 2026 |
| Iceland | max wholesale | 6 | 17 | 02 Sep 2026 |
| Romania | max producer price | 10 | 17 | 03 Sep 2026 |
| Bahrain | retail (max) | 7 | 16 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 15 | 15 | 03 Sep 2026 |
| Spain | PVP con IVA (public price) | 11 | 11 | 05 Sep 2026 |
| Luxembourg | reimbursement | 11 | 11 | 05 Sep 2026 |
| United Arab Emirates | public | 8 | 10 | 31 Aug 2026 |
| Morocco | PPV (public price) | 1 | 4 | 05 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.